Corgentech Changes Name to Anesiva to Reflect Focus on Robust Pipeline of Pain Therapeutics
22 6월 2006 - 6:05AM
PR Newswire (US)
Company Stock to Trade on Nasdaq Under the Symbol: ANSV SOUTH SAN
FRANCISCO, Calif., June 21 /PRNewswire-FirstCall/ -- Corgentech
Inc. (NASDAQ:CGTK) today announced that it has changed its name
effective immediately from Corgentech Inc. to Anesiva, Inc.
(NASDAQ:ANSV) to reflect the company's robust, advancing pipeline
of pain therapeutics. The name change was approved today by
stockholders at the company's annual meeting. The company will
trade under the symbol ANSV when the Nasdaq stock market opens
tomorrow. "Our new name reflects our focus on the development of
improved pain management therapies and on bringing them to market
for patients and healthcare providers as soon as possible," said
John P. McLaughlin, chief executive officer of Anesiva. "Anesiva's
new generation of pain medicines are designed to provide
significant advantages to patients over currently available
products." Anesiva has three novel pain management products in
preclinical or clinical development: o 3268: a fast-acting local
anesthetic that has successfully completed two Phase 3 clinical
trials for the treatment of pain associated with venous access
procedures. Its rapid onset of action within one to three minutes
is significantly faster than the 30-60 minutes of currently
available products. The company anticipates filing a New Drug
Application this summer with the FDA for 3268. o 4975: a
fast-acting, non-opioid analgesic for the management of moderate to
severe pain with the potential to provide relief for weeks to
months after just a single administration. Anesiva recently
reported top-line results from a Phase 2 trial of 4975
demonstrating a statistically significant reduction in pain after
total knee replacement surgeries at day one and day 14 compared to
placebo, and trends in favor of 4975-treated patients measuring
pain at all time points. o 1207: a fast-acting topical local
anesthetic in preclinical development that could be useful in the
management of pain in multiple settings including neuropathic pain.
Anesiva anticipates studying 1207 in a Phase 1 clinical trial in
the second half of 2006. Anesiva's lead products address large
unmet needs in pain management. IMS Health estimates that
approximately $18 billion is spent on prescription pain drugs in
the United States alone, yet current pain management options are
often not optimal due to limited efficacy, inconvenient
administration, long onset of action, short duration of activity,
adverse reactions and/or a tendency to cause physical dependence.
As hospitals compete more fiercely than ever, they increasingly
focus on patient satisfaction to attract patients. As a result,
reducing pain has become a priority with many hospitals seeking to
create "pain-free" environments, particularly in the emergency
room. About Anesiva Anesiva, Inc., is a late-stage
biopharmaceutical company that seeks to be the leader in the
development and commercialization of novel therapeutic treatments
for pain. The company has four drug candidates in clinical
development for multiple potential indications, the most advanced
of which, 3268, has completed Phase 3 clinical trials. Anesiva is
based in South San Francisco, CA. For more information about
Anesiva's leadership in the development of products for pain
management, and an overview of the clinical challenges being
addressed by its product candidates, go to:
http://www.anesiva.com/. Forward Looking Statements This press
release includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995. Words such as "expect," "estimate,"
"project," "budget," "forecast," "anticipate," "intend," "plan,"
"may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions are intended to
identify such forward-looking statements. Forward-looking
statements in this press release include, without limitation,
projected timing of clinical development and other matters that
involve known and unknown risks, uncertainties and other factors
that may cause actual results, levels of activity, performance or
achievements to differ materially from results expressed or implied
by this press release. Such risk factors include, among others:
whether Anesiva can successfully develop new products and the
degree to which these gain market acceptance. Actual results may
differ materially from those contained in the forward-looking
statements in this press release. Additional information concerning
these and other risk factors is contained in Anesiva's quarterly
report on Form 10-Q for the quarter ended March 31, 2006 filed with
the Securities and Exchange Commission under the company's previous
name, Corgentech Inc. Anesiva undertakes no obligation and does not
intend to update these forward-looking statements to reflect events
or circumstances occurring after this press release. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement. DATASOURCE: Anesiva, Inc. CONTACT:
Jennifer Cook Williams, Vice President, Investor Relations of
Anesiva, Inc., +1-650-624-9600, or Web site:
http://www.anesiva.com/ Web site: http://www.corgentech.com/
Copyright
Corgentech (NASDAQ:CGTK)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Corgentech (NASDAQ:CGTK)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024